NGM Biopharmaceuticals, Inc. Corporate Overview

Novel Biology. Powerful Medicines. Transformative Impact.



Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, expected near-term milestones, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially" "predict," "should," "will" or the negative of these terms or other similar expressions. These statements include those related to NGM's advancement of its clinical and preclinical pipeline; the timing, enrollment and results of NGM's clinical trials, including the continued enrollment and announcement of preliminary results of the Phase 2 clinical study of aldafermin (NGM282) in patients with NASH; NGM's option to participate in the economic return of NGM313 or ability to receive milestone payments or royalties from NGM313; the continued development of NGM621; the safety, tolerability and efficacy of NGM's product candidates; NGM's ability to fund its clinical programs and NGM's financial outlook. Because such statements deal with future events and are based on NGM's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of NGM could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in quarterly report on Form 10-Q for the guarter ended June 30, 2019 and other filings that we make from time to time with the Securities and Exchange Commission. Except as required by law, NGM assumes no obligation to update these forward-looking statements after the date of this presentation, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Company Highlights



Aldafermin (NGM282) Wholly-owned, Phase 2b product candidate for treatment of NASH (non-alcoholic steatohepatitis) NGM313 (MK-3655) Insulin sensitizer for treatment of NASH and T2D; Completed Ph1b and licensed by Merck Pipeline of **five** additional product candidates in cardio-metabolic, oncologic and ophthalmic diseases

-

\$\$\$

Strategic collaboration with Merck providing robust R&D support and NGM option on future Merck late-stage programs



Experienced team with highly productive R&D engine generating on average ~1 development candidate/year Multiple **key milestones** and potential **value driving catalysts** expected in the next 18 months

Highly Experienced Team with Proven First-in-Class **Drug Development Track Record**



MANAGEMENT

William J. Rieflin **Executive Chairman**

David J. Woodhouse, Ph.D. Chief Executive Officer and Acting Chief Financial Officer

Aetna Wun Trombley, Ph.D. President and Chief Operating Officer

> Jin-Long Chen, Ph.D. Founder Chief Scientific Officer

Alex DePaoli, M.D. Senior Vice President Chief Translational Officer

Hsiao D. Lieu, M.D. Senior Vice President Chief Medical Officer

Wenyan (David) Shen, Ph.D. Senior Vice President, Biologics

Hui Tian, Ph.D. Senior Vice President, Research

EXTENSIVE PRIOR EXPERIENCE



Humulin

Key Roles in Prior Drug Approvals

(prasugrel) tablets

Repatha

BOARD OF DIRECTORS

William J. Rieflin Executive Chairman, NGM Bio

David V. Goeddel, Ph.D. Lead Independent Director Managing Partner, The Column Group

> Jin-Long Chen, Ph.D. Founder, CSO NGM Bio

Suzanne Sawochka Hooper

Former Exec. VP and GC, Jazz Pharmaceuticals

Mark Leschly

Managing Partner, Rho Capital Partners

David Schnell. M.D. Managing Director, Prospect Venture Partners

Peter Svennilson Managing Partner, The Column Group

McHenry (Mac) T. Tichenor, Jr Managing Partner, Tichenor Ventures, LLC

David J. Woodhouse, Ph.D. CEO and Acting CFO, NGM Bio

Our Expansive Pipeline




	PRODUCT CANDIDATE	PRODUCT DESCRIPTION (DOSING FREQUENCY)	POTENTIAL INDICATIONS	STAGE OF DEVELOPMENT	WORLDWIDE COMMERCIAL RIGHTS	
7 Development Programs	Aldafermin (NGM282)	FGF19 Analog (Once Daily)	NASH	Phase 2b	NGMBio Wholly- Owned	
	NGM313 (MK-3655)	FGFR1c/KLB Agonistic Antibody (Once Monthly)	NASH, Type 2 Diabetes	Phase 1b	MERCK Licensed	
	NGM120	GFRAL Antagonistic Antibody (Long Acting)	Cancer Anorexia/Cachexia Syndrome (CACS)	Phase 1	NGMBio MERCK Option	
	NGM217	Undisclosed (Long Acting)	Diabetes	Phase 1	NGMBio MERCK Option	
	NGM621	Complement C3 Antagonistic Antibody (Long Acting)	Dry Age-Related Macular Degeneration (AMD)	Phase 1	NGMBio MERCK Option	
	NGM386	GDF15 Analog (Once Daily)	Metabolic	Phase 1	NGMBio Wholly-Owned	
	NGM395	GDF15 Analog (Long Acting)	Metabolic	Preclinical	NGMBio Wholly-Owned	

FGF19: fibroblast growth factor 19; FGFR1c/KLB: fibroblast growth factor receptor 1c/beta-klotho; GDF15: growth differentiation factor 15; GFRAL: glial-cell-derived neurotrophic factor receptor alpha-like



Improving Fibrosis Leads to Better Outcomes for NASH Patients




NASH expected to be the #1 cause of liver transplant by 2020¹


Sources: Dulai et al, Hepatology 2017, 65(5):1557-1565; Singh et al, Clin Gastroenterol Hepatol. 2015, 13(4): 643–654; Estes et al, Hepatology 2018, 67(1): 123-133. ¹ Canbay et al, Visc Med 2016, 32: 234-238.



Aldafermin Impacts the Key Drivers of NASH Pathogenesis



Unlike Many Other Drugs in Development, Aldafermin Targets Fibrosis Reversal and Cirrhosis Prevention in Advanced NASH Patients



NGME

Aldafermin: Single Agent with Metabolic and Anti-Fibrotic Efficacy



Only FGF19 agonist in clinical development for NASH → potent activity on FGFR1c and FGFR4



Significant reduction across all non-invasive measures at 12W: MRI-PDFF, ALT/AST, fibrosis biomarkers (ELF, PRO-C3) and bile acid synthesis (C4; Phase 2, Cohorts 1-3)



Rapid reversal of fibrosis (≥ 1 stage) in 42% of patients at 12W (3 mg dose)



Improvements across all other histological measures of NASH at 12W (% of patients with \geq 1 stage improvement; 3 mg dose): steatosis (74%), inflammation (42%) and ballooning (53%)




Durability of effect on non-invasive measures at 24W (Interim analysis, 2H19)



Confirmation of effect on fibrosis/NASH histology at 24W in placebo-controlled trial (early 2020)


NASH Phase 2 Program Provides Foundation for Late Stage Development of Aldafermin



NGMBic

Key Primary and Secondary Endpoints Achieved by Week 12 (MRI-PDFF and ALT)






Source: Aldafermin 1 mg (Cohort 3) and 3 mg (Cohort 2) biopsy cohorts; Preliminary data

Key Primary and Secondary Endpoints Achieved by Week 12 (PRO-C3 and C4)






^{***}P<0.001, **P<0.01, *P<0.05 vs. baseline

C4 = 7alpha-hydroxyl-4-cholesten-3-one Source: Aldafermin 1 mg (Cohort 3) and 3 mg (Cohort 2) biopsy cohorts; Preliminary data

Rapid Regression of Fibrosis at Week 12 in Patients Treated with Aldafermin




Fibrosis Histological Response at Week 12¹ (% of Patients; n=19 in 3 mg dose of Cohort 2, n=24 in 1 mg Cohort 3)



Exploratory Endpoints Achieved: All NASH Histological Parameters Improved at Week 12



NAS Histological Response at Week 12^{1,2} (% of Patients; n=19 in 3 mg dose of Cohort 2, n=24 in 1 mg Cohort 3)



¹ Preliminary data

² NAS: NAFLD Activity Score


Favorable Tolerability Profile



- Over 400 subjects have been dosed with aldafermin and the drug was well-tolerated
- Preliminary data indicates that there were no tolerability signals identified in the NASH population
- Preliminary safety data from the Phase 2 NASH study:
 - Cohort 1: a single serious adverse event (SAE) of acute pancreatitis was reported and assessed as possibly related to study drug
 - Cohort 2: seven SAEs (none of which were considered related to study drug) were reported in five subjects
 - Cohort 3: a single SAE (kidney mass) was reported, which was not considered related to study drug
- The most common adverse events in cohorts 1, 2 and 3 were increased stool frequency, loose stools, nausea and injection site erythema, with the majority being mild


Cholesterol Changes Effectively Managed with Statin Therapy






Serum triglyceride levels decreased and HDL-C elevated with aldafermin treatment

Aldafermin Development Plan



GM

NGM313 (MK-3655) for the Treatment of NASH and Type 2 Diabetes




- Agonistic antibody that selectively activates FGFR1c / KLB to regulate energy metabolism
- Potential to be once-monthly injectable insulin sensitizer for treatment of NASH and T2D
- Completed Phase 1 SAD/MAD study in obese, insulin resistant subjects and Phase 1b study in subjects with NAFLD
- Single dose of NGM313 resulted in **significant reductions in liver fat content and improvement in metabolic markers** based on preliminary data from a Phase 1b study in obese, insulin resistant subjects with NAFLD **after five weeks**
- Well-tolerated across Phase 1 and Phase 1b studies
- Merck exercised its option and licensed NGM313 and other FGFR1c/KLB agonists in 4Q18

NGME




Phase 1b Study in Obese, Insulin Resistant Subjects with NAFLD




Rapid Reduction in HbA1c Without Hypoglycemia After Single Dose of NGM313 (MK-3655)








NGM313 (MK-3655) has Potential to Complement Aldafermin by Targeting NASH Population with T2D





PHASE 2b

NGM313 (MK-3655) Next Steps



- Merck to fund all Phase 2 development costs
- NGM retains an option, when program has advanced to Phase 3, to participate in up to 50% of the economic return of the program
- If NGM does not exercise its option, NGM is eligible for development and commercial milestone payments and tiered royalties ranging from low double digit to mid-teen percentage rates on product sales




Beyond NASH, an Expansive Pipeline in Other Indications

	PRODUCT CANDIDATE	PRODUCT DESCRIPTION (DOSING FREQUENCY)	POTENTIAL INDICATIONS	STAGE OF DEVELOPMENT	-	WORLDWIDE COMMERCIAL RIGHTS	
7	Aldafermin (NGM282)	FGF19 Analog (Once Daily)	NASH	Phase 2b	NGMBio	Wholly- Owned	
Development Programs	NGM313 (MK-3655)	FGFR1c/KLB Agonistic Antibody (Once Monthly)	NASH, Type 2 Diabetes	Phase 1b	MERCK Licensed	NGMBio	
	NGM120	GFRAL Antagonistic Antibody (Long Acting)	Cancer Anorexia/Cachexia Syndrome (CACS)	Phase 1	NGMBio	Option	
	NGM217	Undisclosed (Long Acting)	Diabetes	Phase 1	NGMBio	Option	
	NGM621	Complement C3 Antagonistic Antibody (Long Acting)	Dry Age-Related Macular Degeneration (AMD)	Phase 1	NGMBio	Option	
	NGM386	GDF15 Analog (Once Daily)	Metabolic	Phase 1	NGMBio	Wholly-Owned	
	NGM395	GDF15 Analog (Long Acting)	Metabolic	Preclinical	NGMBio	Wholly-Owned	




Geographic Atrophy (GA) is an Advanced Form of AMD



- Geographic atrophy (GA) is the dry form of advanced AMD, characterized by progressive and irreversible loss of photoreceptors, retinal pigment epithelium (RPE) and choriocapillaris
- GA is typically bilateral and lesion enlargement results into irreversible blindness
- GA affects ~5 million people globally and ~ 1 million people in the US
- Currently no approved treatment for GA

Fleckenstein et al, Ophthalmology 2018, 125(3): 369-390; Friedman et al, Arch Ophthalmol. 2004, 122: 564-572


Complement Activation is Associated with Development of Advanced AMD



Variants in the complement pathway account for the majority of the known genetic risk for AMD


NGMBic

NGM621 Targets Complement C3, Blocking All Three Pathways of Complement Activation




NGMBic

NGM621: A Potent Anti-Complement C3 Antibody



- Antibody that has high binding affinity for human C3 ($K_D < 1 \text{ nM}$)
- Potent inhibition of both classical and alternative pathways of complement activation ($IC_{50} \sim 5-6 \text{ nM}$)
- Potential for QM (monthly) or Q2M (EOM) intravitreal dosing



NGM621 Development




Initiated Phase 1 open-label single dose and multiple dose study in patients with GA

- Primary objective to evaluate the safety, tolerability and pharmacokinetics of intravitreal injection(s) of single and multiple doses of NGM621
 - Estimated enrollment of ~24 patients with GA secondary to AMD
- Study enables a potential Phase 2 POC study in GA
- Favorable tolerability profile observed from 5W GLP toxicology study in monkey
- Program is subject to Merck option to license the program

Our Merck Collaboration: Growth-Accelerating Partnership






¹ Merck has committed to provide R&D reimbursement of up to \$50 million per year. If our R&D expenses exceed \$50 million in a given year, Merck can either reimburse up to an additional \$25 million for use in funding IND-enabling or later-staged activities or to provide us with the equivalent value in in-kind services for such activities.



Momentum with Potential Value-Driving Catalysts



¹ Merck has committed to provide R&D reimbursement of up to \$50 million per year; if our R&D expenses exceed \$50 million in a given year, Merck can either reimburse up to an additional \$25 million for use in funding IND-enabling or later-staged activities or to provide us with the equivalent value in in-kind services for such activities. In lieu of a \$20 million extension fee payable to NGM, Merck will make additional payments totaling \$20 million in R&D funding from Jan 2021-Mar 2022.

NGM Biopharmaceuticals, Inc. Corporate Overview

Novel Biology. Powerful Medicines. Transformative Impact.

